Study identifier:D781AC00001
ClinicalTrials.gov identifier:NCT06271837
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) as monotherapy or in combination with anti-cancer agents for the Treatment of Patients with Selected HER2-expressing Tumors (DESTINY PanTumor03)
Advanced solid tumors (excluding gastric cancer and breast cancer)
Phase 2
No
Trastuzumab deruxtecan, Bevacizumab
All
175
Interventional
18 Years - 130 Years
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
Daiichi Sankyo Co., Ltd.
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Part 1 HER2 IHC 3+ solid tumors (excluding breast and gastric cancer) | Drug: Trastuzumab deruxtecan Trastuzumab deruxtecan by intravenous infusion Other Name: DS-8201a Other Name: T-DXd |
Experimental: Part 2 Cohort A HER2 IHC 2+ solid tumors (excluding breast and gastric cancer) | Drug: Trastuzumab deruxtecan Trastuzumab deruxtecan by intravenous infusion Other Name: DS-8201a Other Name: T-DXd |
Experimental: Part 2 Cohort B HER2 IHC 1+ gynecologic cancers | Drug: Trastuzumab deruxtecan Trastuzumab deruxtecan by intravenous infusion Other Name: DS-8201a Other Name: T-DXd |
Experimental: Part 3 HER2 IHC 3+ or 2+ cervical cancer | Drug: Trastuzumab deruxtecan Trastuzumab deruxtecan by intravenous infusion Other Name: DS-8201a Other Name: T-DXd Drug: Bevacizumab Bevacizumab by intravenous infusion |